

## Journal of Pharmaceutical Advanced Research

(An International Multidisciplinary Peer Review Open Access monthly Journal)

Available online at: [www.jparonline.com](http://www.jparonline.com)

# Application of Quality by Design concepts to Biotechnological products

Parag Das\*, Animesh Maity, Divya Prabhu, S.V. Rajesh Kumar

Oman Pharmaceutical Products Co. LLC, Muscat, Sultanate of Oman.

Received: 01.04.2018

Revised: 10.05.2018

Accepted: 15.05.2018

Published: 31.05.2018

**ABSTRACT:** Biopharmaceuticals also called “biological medicinal products” are medicines whose active drug substance is made by a living organism or derived from a living organism by the means of recombinant DNA and/ or controlled by gene expression methods. Biotechnological drug development is an extensive area still growing and coming into prominence day by day. Since biotechnological product manufacturing is irreversible, highly expensive, and contains so many critical parameters throughout the process, quality control tests applied to the finished product become inefficacious; therefore, maintaining predefined quality is crucial. Quality by Design (QbD), a systematic approach, is designing and optimizing of formulation and production processes in order to provide a predefined product quality by following a risk and scientific-based path. Determining the critical variables for biotechnological products and their manufacturing via risk assessment is the first and most vital stage of QbD approach, before exploring the multivariate relations among the independent and dependent critical variables by mathematical modeling with the assistive technologies like Response Surface Method (RSM), Artificial Neural Network (ANN), and Genetic Algorithm (GA). After modeling, additional knowledge is vested and this provides the chance to find a range in which the product quality is always ensured, called as “Design space”.

### Corresponding author\*

Dr. Parag Das  
Vice President – Technical  
Oman Pharmaceutical Products Co. LLC,  
Muscat, Sultanate of Oman.  
Mail ID. [paragdas@omanpharma.com](mailto:paragdas@omanpharma.com)  
Tel. No. +96897044187.

**Keywords:** Biotechnology, Production, QbD, ICH, Biosimilars, Process development, Risk assessment.

### INTRODUCTIONS:

Quality by design (QbD) is an innovative product development process approach using both existing knowledge and emerging science to identify key “quality” issues in order to address or predict their impact on product attributes and ultimately patients’ health. This can enable a certain freedom to carry out the manufacturing parameters of a product within a pre-approved design space during manufacture, without consulting the regulatory agencies in advance.

The complete backbone in the product development design, according to QbD, consists of the establishment of the Quality Target Product Profile (QTTP) according to which critical quality attributes (CQAs) and critical process parameters (CPPs) are identified, and appropriate control strategies established and implemented. QbD “builds quality into the product instead of testing it.”

The main advantage and disadvantage of QbD are intrinsic to the process itself, as QbD requires an understanding of clinical characteristics and desired product performance already from early on in the development process; criteria are set as the goal at which product formulation and process development are aimed. A QbD approach increases product/process knowledge and understanding, thereby reducing risk of batch failure, but requires significant investment in resources at very early stages of product development where it is often far from clear if the drug candidate will be safe and efficacious in later clinical trials. Of interest is the possibility, enabled by QbD, to improve manufacturing efficiency of the product and facilitate regulatory flexibility in the post-approval setting – thus having the potential of being faster, more straightforward and potentially cheaper in the long run. The latter is assured, for example, by the identification of a product design space. Movements within an approved design space do not need to be notified to regulatory authorities.

The need of understanding and keeping the complex manufacturing processes for biotech products under control, together with reduced overall costs related to development and maintenance of marketing authorization, is the driver for pharmaceutical companies to apply QbD principles during biopharmaceutical development. However, implementing QbD for biotechnology products still represents a challenge due to the complexity of both the manufacturing processes and the product itself<sup>[1,2]</sup>.

Successful implementation of QbD concepts often presupposes a huge amount of cooperative work, involving not only several sectors within a pharmaceutical company (Research and Development, manufacturing, quality control and regulatory affairs), but also regulatory agencies who need to accept the particular concept. General principles of QbD are outlined in the Q8, Q9, Q10 and Q11 guidelines issued by the “International Conference on Harmonisation of Technical Requirements for Registration of

Pharmaceuticals for Human Use” (ICH) leaving room for flexibility in the specific approach to be adopted by the different pharmaceutical companies. However, this increases the possibility for lack of harmonization in the use of definitions, in the overall validation approach, in the application of statistical techniques, and, last but not least, in the information provided in the marketing authorization application (MAA) dossier<sup>[1,2]</sup>.

Collaboration between industry and regulators is ongoing (e.g., a joint EMA-Industry QbD workshop held at the European Medicines Agency in early 2014) in order to reach agreement on implementation of QbD principles, on terminology, definitions, and filing requirements. At present, many issues still need to be addressed and, to date; marketing approval based on a QbD dossier has essentially been granted to only a few products, mainly chemicals. Biotechnology-derived medicinal products, however, are now emerging on the QbD stage. Recently, a marketing authorization, valid throughout the European Union, was issued for an anti-human epidermal growth factor receptor (HER)2 monoclonal antibody (mAb), for use in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. In this paper, we discuss lessons learnt from the evaluation of this pioneer dossier, which should rather be seen as an exemplifying case study than the discussion of an individual dossier. The MAA was filed to regulatory agencies making use of QbD concepts, on the basis of previous knowledge acquired in the manufacturing of other authorized mAbs with different specificities, and adopting risk assessment and decision tools to establish CQAs, CPPs, acceptable process parameter ranges, as well as the drug substance and drug product control systems and process monitoring<sup>[1-3]</sup>.

#### **ICH Guidelines: objectives and history:**

Traditional pharmaceutical manufacturing is accomplished by using batch processing with quality control testing conducted on samples of the finished product. Despite the loss of too many products and investment, this conventional approach has been considered sufficient in providing quality pharmaceuticals to the public for many years. However, innovation in product and process development, process analysis, and process control can provide significant

opportunities for improving pharmaceutical development, manufacturing, and quality assurance<sup>[4]</sup>.

Process change is an expected aspect of pharmaceutical manufacturing. To keep pace with advancing technologies and improvements in the manufacturing process, many process changes are made resulting from increased process knowledge. When a product is first approved, its manufacturing process represents the current technology standard for manufacturing and follows the current standards for regulatory compliance. After approval, the approved process may need to be modified due to changes in market demand, technological advances, manufacturing standards, raw materials sourcing, or manufacturing experience. Traditionally, post approval changes require regulatory agency approval before implementation. The increasing number of new products in addition to the number of marketed products seeking post approval changes has placed a significant burden on the government and industry to submit and review data to comply with existing requirements. Thus, we need to identify a path forward that will enhance substantial product and process knowledge using risk assessment tools and quality systems to ensure product safety and efficacy<sup>[4]</sup>.

Because of all these reasons, the drug industry experienced major developments in production information, quality management systems, and risk management in recent years. The industry developed modern production tools that can assist in ensuring product quality. Thus, Food and Drug Administration (FDA) introduced the amendments in the current Good Manufacturing Practices (cGMP) to the pharmaceutical industry, to improve and modernize the rules that regulate the pharmaceutical product manufacturing and product quality since 2002, in accordance with the developments in the twenty-first century. International Conference on Harmonization (ICH) is a forum for registered institutions and experts from the pharmaceutical industries in the United States (US), Japan, and European Union to harmonize the technical requirements for pharmaceutical products in three regions. It provides up-to-date guidelines bringing a new approach called Quality by Design (QbD) to the pharmaceutical industry. The new series of quality guidelines (Q8, Q9, Q10, and Q11) were published by ICH regarding the QbD concept which was introduced into the FDA's chemistry, manufacturing, and controls (CMC) review process in 2004. Subsequently, in 2005,

the guideline Q8 "pharmaceutical development" of the International Conference on Harmonization (ICH), which focused on the content of the module 3.2.P.2 of the common technical document (CTD), was published to present a roadmap for a proper QbD implementation. These improvements have added new dimensions to the pharmaceutical industry<sup>[5,6]</sup>. The concept of "Quality by Design" has been identified as an approach which has something to do with a developed scientific comprehension of crucial process and product qualities by designing controls and tests on the basis of the scientific limits of comprehension which is determined during the progress, and using the knowledge acquired during the life cycle of the product to improve an amelioration environment permanently in this framework<sup>[6]</sup>.

#### **ICH Q8:**

The Q8 guideline is intended to provide guidance on the contents of section 3.2.P.2 (pharmaceutical development) for drug products as defined in module 3 of the common technical document (ICH guideline M4). The pharmaceutical development section aims to provide a comprehensive understanding gained through the application of scientific approaches and quality risk management on the product and the manufacturing process for reviewers and inspectors.

The guideline also indicates areas where the greater understanding of pharmaceutical and manufacturing sciences leads to flexible regulatory approaches. The degree of regulatory flexibility is predicated on the level of relevant scientific knowledge provided. It is first produced for the original marketing application and can be updated to support new knowledge gained over the lifecycle of a product<sup>[7-10]</sup>.

#### **ICH Q9:**

QbD is a systematic approach to pharmaceutical development for designing and developing formulations and manufacturing processes that can generate a prescribed product quality. In other words, QbD claims that "quality cannot be tested into products; it should be built-in during the designing phase". Based on this, the ICH guidelines Q9, "quality risk management," and Q10, "pharmaceutical quality system," were published. The guideline Q9 offers principles for quality risk management that can be applied to different aspects of drug quality. The purpose of this document is to offer a systematic approach to quality risk management<sup>[7-10]</sup>.

Quality risk management tools can be used in various stages of pharmaceutical operations, such as development, production, laboratory controls, packaging, and labeling, and also in inspection and assessment activities. The quality risk management guideline contains two main principles of the risk management model. These principles explain the risk management process and the terminology and tools used for risk evaluation. The aim of the risk management guideline is to create a common understanding to realize risk management, including risks that cover products, processes, and facilities, and risks that affect robustness of the quality system are evaluated, and controls related to risk mitigation are also performed [7-10]. Consequently, the Q9 explains what risk is, how it is evaluated, and where quality risk management could be applied. It specifically provides guidance on the principles and some quality-risk management tools that can allow making more effective and consistent risk-based decisions by regulators and industry, regarding the quality of drug substances and drug products across the product lifecycle [7-10].

#### **ICH Q10:**

ICH Q10 identifies one multi-purpose model for an effective pharmaceutical quality system which is based on International Standards Organization (ISO) quality concepts and it contains applicable GMP regulations and complements ICH Q8 and ICH Q9. ICH Q10 is a pharmaceutical quality system model that can be implemented throughout different stages of life cycle of a product. Therefore, whether the content of ICH Q10 is additional to the current regional GMP requirements or not is optional. ICH Q10 demonstrates industry and regulatory authorities' support for an effective pharmaceutical quality system to enhance the quality and availability of medicines around the world for public health. Applications of Q10 guideline enables innovation and incessant improvement and empowers the link of pharmaceutical progress. ICH Q10 should be practiced in a way that is appropriate to each product's lifecycle phase [7-10].

#### **ICH Q11:**

ICH Q11, "development and manufacture of the drug substances," was published by ICH in 2012. Q11 was created for drug substances, including biotechnological and biological entities, and is related to drug substance manufacturing and development. Various

pharmaceutical development and drug substance understanding approaches are described, and Q11 serves as a guideline on the type of information that should be provided in module 3 CTD sections 3.2.S. 2.2–3.2.S.2.6 [7-10].

#### **ICH Q12:**

ICH Q12, "technical and regulatory considerations for pharmaceutical product life cycle management," is intended to work in compliance with ICH Q8–ICH Q11 guidelines and will give an opportunity to the management of post approval changes in a more predictable and efficient way throughout the life cycle of the product. After complete pursuance of this guideline, upgraded innovation and continual improvement, and more robust quality assurance and reliable supply of product will be expected. It will allow regulators to better understand, and have more confidence in a firm's pharmaceutical quality system (PQS) for management of post-approval changes [7-10].

#### **Biologics and biosimilars – understanding the basics of development:**

Key differences between biologics and small molecule drugs. There are numerous differences between biologics (such as proteins, which are defined by the FDA as being greater than 40 amino acids) and small-molecule drugs. For example, biologics are proteins that are typically much larger than chemically synthesized small-molecule drugs, exhibit a high degree of structural complexity, including primary, secondary, tertiary and possibly quaternary structures, and are subject to post-translational modifications. Another important characteristic of these biologics is that they are potentially immunogenic, that is, capable of eliciting an immune response when administered [11,12].

The manufacturing process for biologics is more complicated than that required for small molecule drugs. Unlike small molecule drugs, which are produced through chemical synthesis, biologics are manufactured in living systems, and their development typically involves cloning and expressing the gene sequence of interest into a specific cell type, fermentation and purification of the final product. Manufacturing of biologics can undergo changes during the process (e.g. because of regulatory requirements or a need to improve manufacturing efficiency, product quality and/or yield); such changes could impact the quality, safety and efficacy of the final product. Although usually without

clinical consequence, changes in the manufacturing of a biologic can necessitate a preclinical and clinical re-evaluation of the biologic, termed a comparability exercise. The International Conference on Harmonization (ICH) Q5E guidelines outline the necessary steps to compare batches of biologics to evaluate whether a manufacturing process change could have an adverse impact on product quality, efficacy or safety, including immunogenicity. This evaluation can be based on an analysis of product quality attributes and, in some cases, supporting preclinical and/or clinical data. Finally, the characteristics of biologics themselves, even under the same manufacturing conditions, can change over time. This phenomenon of changing manufacturing condition is known as drift [11,12].

### QbD road map:

QbD is a systematic product development approach that begins with predefined objectives and emphasizes understanding of the product and process based on firm science and quality risk management, as defined in ICH Q8 guideline (Fig 1). Quality risk management and knowledge management are the two basic components of QbD. QbD is a methodical, erudite, risk-oriented, holistic, and proactive approach to pharmaceutical progress that begins with predefined objectives, and underlines product and process comprehension and process control. QbD requires that quality-improving erudite methods might be used upstream in the research, progress, and design phases to ensure that quality is designed into the product process at the earliest possible phase [13,14].

A vital component of QbD is comprehension of the needs of the patient and the certain quality attributes of the product concerned to security and impressiveness. Thereby, to apply QbD, it is crucial to have a principal comprehension of the functional relationships among patient necessities, product quality attributes, analytical abilities, and the production process. QbD works inside the design space (DS) obtained by considering critical formulation and process parameters and so there is no need for product quality verification through final quality test.

This knowledge is gained during development and grows with more manufacturing experience through process characterization, scale up, technology transfer, manufacture, and increased patient exposure to the product. This approach makes it feasible to use data gathered from development works performed to create a

design space for achieving continuous development. By this way, it is possible to ensure changes in the trade with the change control method, without the need for confirmation from the authority. Regarding the life cycle of the product, the most up to date pharmaceutical and engineering information is used [13,14].

A complete QbD study should include the following four key elements: (i) define a target product quality profile (goals) based on prior scientific knowledge; (ii) design product and manufacturing processes that satisfy predefined goals; (iii) identify potentially high risk attributes and/or parameters and sources of variability by using risk assessment and scientific knowledge to obtain the design space with controlled experimental studies; and (iv) develop a control strategy to control manufacturing processes to produce consistent product quality over time by operating within the established design space, thus assuring that quality is built into the product during the manufacturing, storage, and distribution of the product. Implementation of QbD-based strategies in pharmaceutical development would provide excellence and significant time shortening in product development, and enormous flexibility in regulatory compliance.

It has been emphasized before if the principles described in the ICH Q8, Q9, and Q10 guidelines are implemented together in a holistic manner, this will ensure further that the patient will receive product that meets the critical quality attributes (CQAs) as per the standards of Health criteria as given in Fig 2 [15,16].

### Determination of quality targets [17,18]:

In order to design quality into a product, the requirements for the product design and performance must be well understood in the early design phase. By beginning with the end in mind, the result of development is a robust formulation and manufacturing process with an acceptable control strategy that ensures the performance of the drug product.

**Target product profile (TPP)** describes the general objective of the pharmaceutical product development program and provides information about the development works. ICH Q8 needs specifying of properties crucial for the quality of the prepared pharmaceutical product, in regard to intended use and route of administration and valuation of intended use of the product and route of administration is performed with the TPP. Pharmaceutical companies will use the desired labeling information to establish a target product




Fig 1. Road map of Qbd.




Fig 2. Differences in the source of information throughout product development of biosimilars and original biologics: Diamonds represent decision points where risk assessments are performed to select critical variables for the next step of product development.

Pharmaceutical companies will use the desired labeling information to establish a target product profile that describes anticipated indications, contraindications, dosage form, dose, frequency, pharmacokinetics, route of administration, maximum and minimum doses, presentation of pharmaceutical product, and target patient population.

**The quality target product profile (QTPP)** is derived from the desired labeling information for a new product and defined as a prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product. The QTPP will help identify critical quality attributes such as potency, purity, bioavailability or pharmacokinetic profile, shelf life, and sensory properties.

A **critical quality attribute** is a physical, chemical, biological, or microbiological feature or property that should be within a proper limit, range, or distribution to provide the required product quality. The concept of criticality can be used to explain any feature, importance, or characteristics of an active substance, component, raw material, finished product, or device; or any process characteristics, parameters, conditions, or factors in the finished product.

#### **Determination of critical parameters:**

A material attribute or process parameter is critical when a realistic change in that attribute or parameter can significantly impact the quality of the output material.

The parameter expresses a measurable or countable characteristic of a system or process. Parameters are usually considered as features related to manufacture, such as temperature and mix speed, or as characteristics of equipment or process. Features are considered as characteristics of materials (such as melting point, viscosity, and sterility).

However, it must be noted that there are no absolute borders between features and parameters. Quality attribute hazardousness is initially depended on burden of harm and does not change as a result of exposure management. Process parameter hazardousness is attached to the parameter's effect on any crucial quality attributes. It is depended on the probability of occurrence and discoverability, so it can change as a result of exposure management” [19,20].

#### **Quality risk management** [20-23].

The importance of quality systems has been affirmed in the pharmaceutical industry too, and it is becoming

apparent that quality exposure management is a precious compound of a sufficient quality system.

Commonly, risk is defined as the combination of the probability of occurrence of harm and the severity of that harm. Regarding pharmaceuticals, although there are various stakeholders, including patients and medical practitioners as well as government and industry, the protection of the patient by managing the risk to quality has prime importance.

ICH Q9 quality risk management provides documented, transparent, and reproducible methods to accomplish quality risk management process steps which are demonstrated in Fig 3, based on current knowledge about assessing the probability, severity, and sometimes discoverability of the risk. According to the principle, there are two initial principles to consider in quality risk management implementation:

- The valuation of the risk on quality should be dependent on scientific knowledge and accordingly concerned to the protection of the patient; and

- The level of endeavor, circumstance, and documentation of the quality risk management process should be measured with the risk level of the parameter.

Still, traditional approaches like empirical and/ or internal procedures continue to provide useful information on topics such as handling of complaints, quality defects, deviations, and allocation of resources. It has been noted that the pharmaceutical industry and regulators can access and manage risk using recognized risk management tools and/ or internal procedures (e.g., standard operating procedures). Some of these tools presented in the ICH Q9 guideline are given below: Basic risk management facilitation methods like flowcharts; Failure mode effects analysis (FMEA); Fault tree analysis (FTA); Hazard analysis and critical control points (HACCP); Risk ranking and filtering; and supporting statistical tools.

It should be proper to comply with these tools for use in certain areas concerned to the medicinal material and the medical product quality. Quality risk management procedures and the adjuvant statistical implements can be utilized in combination. Combined use provides flexibility that can facilitate the implementation of quality risk management principles. According to the guideline, it is important to note that it is neither always appropriate nor always necessary to use a formal risk management process like recognized tools and/ or in-house procedures.

The influential quality risk management approach can further provide the high quality drug (medicinal) product to the patient for ensuring a proactive means to define and control potential quality issues during progress and production. Besides, quality risk management usage can leverage the decision making when a quality matter comes in sight. The influential quality risk management is able to support an erudite and practical approach to decision making. Appropriate use of quality risk management can facilitate but does not obviate industry's obligation to comply with regulatory requirements and does not replace proper communications between industry and regulators.

**Risk assessment:**

A well-defined problem description or risk question is the beginning of quality risk assessment. When the risk in question is well defined, an appropriate risk management tool and the types of information needed to address the risk question will be more readily determined. Prior product knowledge is a key in risk assessment and consists of the accumulated laboratory, nonclinical, and clinical experience for any specific product quality attribute. It also can include relevant data from similar molecules and data from literature references. This combined knowledge provides a rationale for relating the attribute to product safety and efficacy. Ishikawa (fishbone) diagram is an effective tool to capture a list of potential process inputs that impacts variation. Mapping the production process using a process flow diagram is beneficial to define the scope of the risk assessment process. FMEA or use of a prioritization matrix is helpful in identifying the process inputs that impact quality attributes.

For *Risk identification*, we use the information to identify hazards referring to the risk question or problem. We ask the “What might go wrong?” question, including identifying the possible consequences.

*Risk analysis* is used to estimate of the risk related with the identified hazards by some risk management tools; we can detect the harm with its role in the estimation of risk. Questions such as “What is the likelihood (probability) it will go wrong?”, “What are the consequences (severity)?” must be asked to analyze the risk.

*Risk evaluation* compares the identified and analyzed risk against given risk criteria. Risk evaluations consider the strength of evidence for all three of the fundamental questions.

**Risk control:**

Risk control decides the level of acceptance of risks which is used for risk control should be proportional to the significance of the risk including benefit-cost analysis, to understand the optimum level of risk control process which might focus on questions are is the risk above a reasonable level, what can be done to diminish or obviate risks, what is the proper balance between advantages, risks, and resources, are new risks introduced as a result of the identified risks being controlled.

*Risk reduction* contains the actions taken to weaken the burden and possibility of harm. The application of risk reduction can introduce new risks into the system.

*Risk acceptance* can be a decision to accept the residual risk or it can be a decision where residual risks are not specified. For some types of harms, it might be agreed that an appropriate quality risk management strategy has been applied and that quality risk is reduced to an acceptable level.

**Risk review:**

Risk management should be a lifelong part of the quality management process. The risk management process should be reviewed to include new knowledge and experience. The frequency of any review should be based on the risk level. Risk review might include reconsideration of risk acceptance decisions.

**Risk communication:**

Risk communication is the sharing of information about risk and risk management between the decision makers and others. Parties can communicate at any stage of the risk management process. The outputs of the quality risk management process should be documented. The interested parties might be regulators and industry, industry and the patient, industry or regulatory authority, etc. The information will cover the probability, severity, acceptability, control, treatment, discoverability, or many other aspects of risks to quality.

**Design of experiments** <sup>[24-27]</sup>:

While generating design space, parameters to be included or excluded to multiple variation analysis and/or model development should be assessed and selected carefully. There are significant differences between process requirements for large and small molecules, as well as differences between active substance and finished product production phases. When process parameters are defined, number of parameters for multifactorial analysis should be reduced. Generating






Fig 3. Flow diagram of quality risk management process.




Fig 4. QTTP and process understanding flow chart for biological products.




Fig 5. Standard production process flow diagram (biotechnological products).




Fig 6. Control strategy for upstream and downstream processes of biomanufacturing.




Fig 7. Control strategy for drug substance and final product processes.

a design space that includes all parameters that could affect the quality of a product can be long acting and exhausting. Because of this, risk analysis instruments can be used to point at parameters really affecting a CQA in the finished product. Once the CQAs, CPPs, and CMAs are associated with inputs to the process, experiments can be efficiently designed to develop predictive models and confirm causal relationships, through a risk assessment. In recent researches, design of experiments (DoE) has been found as a more efficient system, because it requires less experimental runs, and includes a wider “knowledge space” than traditional changing experimentation with one factor at a time. Consequently, it is more influential in interrogating conceivable interactions between process factors, avoiding artifacts’ such as empirical aggregate and work order with randomization, and making use of hidden replication, and hereby in having better sensitivity for determining significant effects. The factors to be studied in a DoE could come from the risk assessment exercise or prior knowledge. For DoEs with sole or poly unit operations that are used to institute CPPs and/or to define design space, the including of under mentioned information in the submission will extensively assist the valuation by the setters:

- Rationale for selection of DoE variables (including ranges) is risk assessment with alternative or different other instruments. In order to reduce the experiment load necessary for model verification or experiment design, usually it is also possible to divide parameter sets into logical groups. Working on parameters related to single unit operations can allow small groupings be made in product development.
- Any evidence of change in raw materials like medicinal material and/or excipients that would have an effect on approximations made from DoE studies.
- Listing of the parameters that would be kept constant during the DoEs and their individual values, consisting of comments on the effect of scale on these parameters.
- Type of empirical current design and a verification of its properness, containing the strength of the design.
- Factors under study and their ranges can be presented in a tabloid format. Supporters should figure out if the factors are abided to be measure-dependent.
- Reference to the type of analytical methods used to evaluate the data and their suitability for their intended use.
- Results and statistical analysis of DoE data showing the statistical significance of the factors and their interactions, including predictions made from DoE studies relevant to scale and equipment differences.

#### **Creating design space:**

Design space is defined as “multidimensional combinations and interactions of input material variables

and process parameters with proven assured quality.” Boundaries of the design space should be very well defined. Information should be provided on which parameters and ranges are included in the design space. Comprehensive information about design of experiments and statistical methods should be included in the application <sup>[26-28]</sup>.

In developing design spaces for existing products, multivariate models can be used for retrospective evaluation of past production data. Design spaces can be based on scientific first principles and/or empirical models. An appropriate statistical design of experiments includes a level of confidence that is valid for the entire design space, including the edges of an approved design space. Additional development knowledge and understanding contributes to design space implementation and continual improvement therefore a design space can be updated over the lifecycle. Risk assessments define the focus of development studies and define the design space as part of the risk management process. Different approaches can be considered when implementing a design space, e.g., process ranges or feedback controls to adjust parameters during processing. The design space associated with the control strategy ensures that the manufacturing process produces product that meets QTPP and CQAs all the time <sup>[26-28]</sup>.

The design space has been instituted and verified after the process, the regulatory filing would include the reasonable ranges for all key and crucial operating parameters, and a more restricted operating space typically described for drug products. Only movement outside the DS is accepted as change, which typically initiates a regulatory post-approval change process. Activities within the DS are not considered changes. The filing would contain the purified product design space at the same time, definition of the control strategy, outcome of the verification exercise, and plan for process monitoring. The filing could contain procedures in the QbD paradigm at the same time, for instance, comparability or expanded change protocols, which would permit further suppleness in changes concerning pre confirmed criteria that have been complying with between the applicant and the setter <sup>[26-28]</sup>.

#### **Control strategy:**

The control strategy is a set of planned controls, arising from existing product and process comprehension that warrants process performance and product quality. The controls can contain parameters and attributes, and it is concerned to the medicinal and drug product materials and components, facility and equipment operating conditions, in-process controls, characterization testing, and the relevant methods and density of observation and audit, comparability tests and stability testing” <sup>[29]</sup>.

The probability of a negative impact on product safety and efficacy can be minimized by a holistic approach to the control strategy. The aim of a control strategy for a product is to provide that influential controls are in place to pursue the risks connected with the product at a tolerable level. Therefore, the understandings of risk management and control strategy are profoundly associated and the use of risk assessment in creating the control strategy is unique to the QbD approach. The control strategy creates layers of protection that reduce the risk of the hazards creating actual harm. Additional emphasis on process controls should be considered in cases where products cannot be well-characterized and/or quality attributes might not be readily measurable due to limitations of testing or discoverability [29].

When designing the control strategy, the identification and linkage of the CQAs and CPPs should be considered. A well-developed control strategy will reduce risk but does not change the criticality of attributes. The control strategy plays a key role in ensuring that the CQAs are met, and hence that the QTPP is realized. A well-designed control strategy that results from appropriate leveraging of Q8/Q9/Q10 principles leads to reliable product quality and patient-safety profiles.

Design space boundaries are an integral part of a comprehensive control strategy. The control strategy for a product is expected to evolve through the product lifecycle. As product knowledge evolves and changes including acceptance criteria, analytical methodology, or the points of control (e.g., introduction of real-time release testing), there is the possibility of less reliance on end-product testing. The permanent process validation is an approach which permits a firm for observing the process and make amendments to the process and/or the control strategy correspondingly. If multivariate prediction models are used in systems that pursue and update the models help to warrant the permanent convenience of the model within the control strategy [29,30].

#### **Process analytical technology:**

Process analytical technology (PAT) is defined as a system for analyzing and controlling manufacturing through timely measurements of critical quality and performance attributes of raw and in-process materials and processes during the processes. This is for the goal of ensuring final product quality.

The goal of PAT is to support principles of QbD that emphasize fundamental process understanding and control focus to maximize process efficiency. The main Process analytical technology tools can be divided into two main groups as multivariate data acquisition and analysis and modern process analyzers or process analytical chemistry tools [31].

#### **Continual improvement:**

Continuous improvement is an essential factor in a modern quality system that aims developing efficiency by leveraging a process and removing wasted endeavors in production. These endeavors are being initially directed toward in order to diminish variability in process and product quality attributions. Examples of continuous improvement include actions like adjusting a set point of a process, advanced control techniques, redesigning a process step, simplifying documents, installing online measurements, changing the design space and updating the control strategy data for continuous improvement [32].

#### **Benefits of the QbD implementation:**

The benefits of QbD span the product lifecycle and center on areas that have the most impact to the safety, efficacy, and quality of the product and encourage innovation and continuous improvement to the product long after initial approval to leverage knowledge gained and technology advancements. From the perspective of manufacturers, better understanding of product/ process, development of more effective processes and less regulatory requirements are possible. In addition to these, it permits for concepts crucial and non crucial parameters in improving design space, ensures the opportunity for centering upon significant parameters of product quality in verification works. QbD provides potential opportunities for real-time quality control and reduction of the end point (QC) release testing; decreased final product testing and lower batch release costs, reduced batch failure rates; so lower operating costs from fewer failures and deviation investigations; also reduced raw material and finished product inventory costs; ensures better design of the products with fewer problems in manufacturing; allows for the implementation of new technology to improve manufacturing without regulatory scrutiny; and ensures less complication during review, so that reduced deficiencies and quicker approval is possible. Another benefit often noted is the promise of less burdensome regulatory reporting of post approval changes. Even without the incentive of less burdensome regulatory oversight [33,34].

#### **QbD approach for biotechnology products [34-36]:**

As in past few decades, manufacturers define a process and aim to perform the process consistently in a way that the critical parameters are controlled within a narrow range in order to reduce variability in product quality for biotechnology products. However, because the process controls are fixed in this approach, any variability in raw materials, environmental controls, and/or process operations manifests as variability in product quality and results in lot failures. The international ICH Q8 (R2), Q9, and Q10 guidelines provide the foundation for

implementing QbD to the biotech products, however, involve some differences and complexities.

A key element in implementing QbD for biotechnology products is engineering the molecule itself. A number of strategies are currently used by investigators to alter the properties of the molecule to achieve the desired balance among efficacy, stability, safety, and manufacturability. Realization of the structure and functional attributes of therapeutic proteins, including monoclonal antibodies (MAbs), is crucial to create the design space, because that understanding facilitates the selection of requested quality attributes through the molecular design while ensuring that bioactivity of the protein therapeutic is maintained.

**Table 1. Types of chromatographic methods used in downstream process of biotech products.**

Chromatographic method	Principle
Size-exclusion chromatography	Size/shape difference
Ion-exchange chromatography	Net surface charge difference, pH
Affinity chromatography	Biological affinity between drug substance and ligand (M-Chelates, lectins, dyes)
Hydrophobic interaction chromatography	Surface hydrophobicity difference, polarity
Immunoaffinity	Purification of Mab, based on affinity between Mab and antigen (Protein A and G)
Hydroxyapatite chromatography	Complex interaction between drug substance and media
Immobilized metal-ion affinity	Metal-ion binding
Chromato-focusing	Isoelectric point difference

Extensive data about the product and its manufacturing process is required for QbD implementation. It is not possible to evaluate the effect of every variable numerous variables and attributes that show interaction to impact safety and efficacy of a biotechnology product. Statistical approaches, such as DOE and multivariate data analysis (MVDA) along with risk management tools, can help to ensure that resources are spent on the most important tasks. Currently, authorities have not submitted the clear guidance on what they take into consideration to be a reasonable risk for biotechnology products. The industry is able to work with health authorities for sharing examples of process changes and to ensure an evaluation for post approval variations and notification categorization. There is no clearly defined mechanism to share process understanding for well-understood processes and products.

According to information given above, basic QbD approaches for biotechnological products and their manufacturing are QTTP and CQAs. Because of unique nature of the bioproducts/ bioprocesses, multivariate QTTP parameters are at stake. For this reason, QbD approaches for monoclonal antibodies will be considered in the chapter.

In Fig 5, basic bioprocessing steps are given for better understanding of QTTP and CQAs for biotechnological products. In the downstream process, various purification methods are integrated as seen. Selection of one of the chromatographic methods given in Table 1 depends on the drug substance characteristics, cell line and bioreactor choices, and other process-related properties.

In downstream processing of MAbs, purification steps are similar to the other biotech products but also contain specific methods such as protein A chromatography which is commonly used for its IgG (Mab) affinity. This method distinguishes itself by high selectivity toward IgG-type antibodies, high flow rate, and capacity.

In large-scale production of biopharmaceuticals, there are optimization criteria for bioprocess development; concentration, volumetric productivity, yield (high titer), and quality (sequence, purity, glycosylation pattern, activity). Optimization begins with identification and characterization of the drug molecule as well as its mode of action. In the light of this information; cell culture processing (cell engineering, production cell line selection, type of bioreactor and critical parameters, feeding strategy (batch, fed-batch, perfusion, continuous), downstream process steps and parameters, process monitoring, analytics and formulation studies) is designed in compliance with regulatory requirements .

In terms of identification and characterization, monoclonal antibodies (MAbs) can be considered as an example for drug-substance properties. MAbs are produced by hybridoma technology and its basic concept is producing identical antibodies and simply includes these steps: a) Immunization of mouse with antigen, b) Isolation of b cells (contains antibodies), c) Cell fusion with myeloma cells (immortal B cell cancer cells), d) Screening and selection of hybrids and propagation, e) Selecting positive clones, freezing the clones and f) Production of ascites and harvest specific antibody

MAbs consist of constant Fc regions and constant/variable Fab regions. Fc regions have heavy chains, while Fab regions have both heavy and light chains. The Fc region is responsible for biological activity. Variable light chains (VL) of the Fab region are responsible for antigen recognition and binding. There are four types of MAbs used for therapy; murine, chimeric, humanized, and human MAbs. Murine MAbs consist of overall murine amino acids, while chimeric MAbs' only variable regions are murine originated,

humanized Mabs' complementarity determining regions (CDRs) are murine originated, and human IgG consists of entirely human amino acids.

Humanized and human Mabs are preferred for their reduced risk of heterogeneity and negative impact on bioactivity. Determination of critical attributes and parameters for Mab products depends on overall structure of Mab, cell clone, and media. Complementarity determining regions (CDRs) of the heavy and light chains have potential glycosylation, deamidation, and oxidation sites, which pose risks such as undesirable glycosylation profiles, disulphide bond formation, and oxidation.

Product heterogeneity is a common problem for all recombinant biotechnological products as well as for Mabs. This could occur either in cell culture process or downstream process and eliminating these variants all along manufacturing process is one of basic approaches of QbD. These variants such as aggregates, deamidation and oxidation products, and different glycosylation patterns strongly affect product's quality, potency, bioavailability, and immunogenicity which could be fatal. In Fig 6 and 7, key process attributes and related critical parameters are outlined in parallel with biomanufacturing steps and further information is given within the article.

Cell line, bioreactor, and medium selection and design are based on cell culture process approaches. Control strategies of pH, oxygen (O<sub>2</sub>), carbon dioxide (CO<sub>2</sub>), temperature, and pressure are determinant for optimization and scale up:

- pH control strategy; basically based on correlation between CO<sub>2</sub> addition and base addition which is related to osmolality, pH, and CO<sub>2</sub>.
- O<sub>2</sub> control strategy; depends on agitation, gas flow rate, and orifice diameter which is related to dO<sub>2</sub>, dCO<sub>2</sub>, shear forces, mixing, and bubble-size distribution.
- Temperature control strategy; based on temperature, which is related to O<sub>2</sub> and CO<sub>2</sub> solubilities.
- Pressure control strategy; based on pressure, which is related to O<sub>2</sub> and CO<sub>2</sub> solubilities.

According to these attributes, physical parameters such as gas flow rate, agitation speed, shear stress; chemical parameters such as dO<sub>2</sub>, dCO<sub>2</sub>, pH, osmolality, and by-product and substrate metabolites and biological parameters such as cell viability and concentration are critical parameters for the cell culture process. Even minor variations in these parameters could have very strong impact on productivity, product quality, and potency. Thus, these parameters must be characterized and optimized. Some of these parameters are measured by direct connection to the operator but some need to be measured via intervention. For example, viability is measured through cell counting tests such as hemocytometer.

Before selecting the cell line, small scale production of chosen cells (*Escherichia coli*, yeast, insect cell, mammalian cells) are carried out and the cell with best performance in terms of activity, speed, and solubility is selected for large-scale production. Post-translational processing and stable expressions are critical parameters for selection. For example, mammalian cells (CHO, mouse myeloma cells) have closer glycosylation pattern to human and ensure stable expression, thus these cells are commonly used for Mab production.

**Table 2. Drug product specifications in biotechnological manufacturing.**

Quality attribute	Analytical assay	Quality assessment criteria
Molecule integrity/weight	PM/MS, cDNA sequence, IEF, CE-SDS or SDS-PAGE	Amino acid sequence/antibody mutation
Bio-potency Color, clarity	Immunoassay, biological activity tests Colorless, clear	Target antigen binding affinity
Aggregation/fragments	HP-SEC, electrophoresis	High levels of aggregation, risk of immunogenicity
Glycosylation	HPLC or CE based glycan assay	High levels of different glycosylation forms
Charge heterogeneity	IEF, ion exchange chromatography, or HPLC	High levels of acidic or basic variant/peak
Process related impurities	Immunoassay, DNA-hybridization, Q-PCR, electron microscopy, <i>in vivo/in vitro</i> assays, spectral analysis	Avoid HCP, leached Protein A, DNA, viruses, cell culture medium proteins
Particulate matter	Visible/sub-visible particles USP	Meet USP 788 requirement
Bioburden/endotoxin	LAL test	Meet USP 85 requirement
Thermal stability	DSC	According to specified temperature

Bioreactor and culture media selection and design approaches should meet defined product quality, productivity, and cell-line specifications. Bioreactor is operated by batch, fed-batch, or continuous modes and the choice of bioreactor based on two criteria; productivity and sterility. Continuous systems ensure

high productivity but cleaning is a matter of fact. Disposable bioreactor systems seem to be a good alternative for production; however, they need to be optimized. Critical parameters for design strategy are; reactor type, mixing, temperature, density, shear stress, gas exchange (O<sub>2</sub>-CO<sub>2</sub>), perfusion rate, and ease of cleaning.

Commonly used cell culture medium supplements consist of glucose, amino acids, inorganic salts, vitamins, growth factors, and animal component free hydrolysates. However, medium ingredients vary due to the high diversity of cell culture properties and medium optimization becomes compulsory for optimal growth of the culture.

Basic approaches of the feeding strategy are; maintaining culture viability, promoting growth, increasing productivity and cell density, cost, and time-effectiveness for industrial- scale production. This requires optimization of feed composition in a timely manner and balancing between nutrient consumption and by-product accumulation (ammonium lactate) which is specific for individual cell lines. Combination systems with high-throughput screening and/or statistical design of experiment (DOE) approaches provide ideal formulations for achieving the maximum cell growth and volumetric productivity. Using antiapoptotic molecules is another approach for prolonging cell viability to increase productivity.

Optimization approaches in downstream processing (DSP) are; yield, purity, productivity, larger process capabilities, and faster process development. DSP based on various filtration and chromatographic operation units, which consist of viral-inactivation and final sterile filtration steps. Removal of contaminants and impurities such as residual cell, media components, host cell protein (HCP), residual DNA, product variants, adventitious viruses, endotoxin, aggregates, and other process related impurities is very crucial for producing products suitable for human use. Among other impurities; product variants, aggregates, and host cell protein (HCP) are most important in activity, efficacy, or safety aspects. First purification step is recovery of the drug substance from cell culture and removal of cell/cell debris, fluid. This process is operated by centrifugation/ultrafiltration and if needed microfiltration steps. These steps are determinant for success of further purification process. Chromatographic steps are critical for high degree of purity and recovery. Design of ligands/matrices of chromatographic methods should be optimized for shorter residence time, higher flow rates, and longer lifecycles, which results in increased binding capacity and improved removal of impurities in washing steps. Primary critical parameters for optimization are; viability, yield, aggregates,

isoforms, HCP, residual DNA, and turbidity. Most of the overall manufacturing costs derive from downstream processing and increase in parallel with higher yield. The main approach for integrating purification steps is increasing titer with cost-cutting measures. Process development is achieved by PAT-QbD systems, high-throughput screening, continuous processing, small-scale/parallel facilities, and integration of modeling

Drug product quality attributes and criteria are given in Table 2 and the main goal of the QbD design is to match these criteria and guarantee defined quality for drug product at the end of the manufacturing process. At this point, process monitoring by biosensors is very critical throughout manufacturing. Especially monitoring of biomass and cell volumes is the most important. Primary physical, chemical, and biological parameters monitored by sensors are genetic/metabolic analysis, biomass/viability, product characteristics, product concentration, impurities, temperature, osmolality, nutrients, metabolites/substrates, pH, dissolved O<sub>2</sub>, volume/weight, CO<sub>2</sub> rate, flow pressure, stirrer speed, viscosity, and side components. Also, biosensors should match some criteria in order to be valid for quality assurance; such as robustness, reliability, accuracy, reproducibility, analysis frequency, selectivity, sensitivity, linearity, ease of cleaning, and sterility.

#### **Challenges of applying QbD in Biopharma Development** <sup>[36-38]</sup>:

There are of course some challenges in implementing the QbD approach like training, which is a major challenge; therefore, regulatory authorities and industry should conduct the training program for the implementation of the QbD concept.

It is relatively a new concept to the pharmaceutical industry and there is still a lack of understanding and trust among all parties so it is important to share proprietary information with especially regulatory groups.

Associated costs to implement QbD in product development, manufacturing unit operations (business and marketing decisions), different regulatory processes (BLA, NDA, ANDA, follow on, and so on), and associated regulatory practices and culture are current concerns and establishing balance between QbD based versus traditional demonstration of quality is in transition.

With much of the science of biological molecules now more firmly understood, there is an increasing drive for the biopharmaceutical sector to follow small molecule pharma down the QbD path. The gradual adoption of QbD for biopharmaceutical development is being prompted not only by experience from conventional pharma, but also by the expectations of regulatory



agencies. This is reflected in regulatory guidelines such as ICH Q11: Development and Manufacture of Drug Substances (Chemical and Biotechnological/Biological entities). Furthermore, the greater understanding required to drive QbD has the added advantage of building transferable knowledge, a particularly valuable benefit for an industry at a relatively early stage of development. However, implementation presents some substantial challenges – starting with understanding what exactly QbD is.

### THE STEEP LEARNING CURVE OF QbD FOR BIOLOGICS<sup>[38-40]</sup>:

Currently, the biopharma industry faces some of the same practical difficulties that inhibited the early implementation of QbD in conventional pharma. Silo departmentalization complicates the justification of additional investment in R&D on the basis of enhanced return during commercial manufacture. And there is, as yet, relatively little experience of applying QbD to biologics, meaning that there is a steep learning curve to climb. In addition, there are also some unique difficulties in applying QbD to biopharmaceutical development. A primary issue is the complexity and heterogeneity of biopharmaceutical products, which far exceeds that of their small molecule counterparts. In addition, the science underpinning the successful development and application of biologics is still evolving. Both of these factors make it difficult to robustly identify CQAs and securely link them to CMAs and CPPs, and impact scale up and technology transfer which are more complex with biologics, and at the same time far less well-established. Other factors impacting the application of QbD within biopharma include:

- Ease of product characterization – as cells from living organisms exhibit much higher variability than their small molecule, chemical counterparts, it can be difficult to securely quantify the potency of a biologic and/or to characterize any impurities present.
- Process variability – biopharmaceutical manufacturing processes tend to be associated with far higher variability than those used in conventional pharma. This is an issue further complicated by the lack of established and effective process monitoring tools.
- Stability – a major issue in the biopharmaceutical industry, where processes such as protein aggregation may not only diminish the therapeutic effect of a drug but also trigger an immunogenic response. While chemical drug substances often exhibit high stability, biologics can be extremely sensitive to the environment in which they are held.

The net result of this complexity is that the implementation of QbD within biopharma calls for a significant level of detailed information gathering. The next challenge, therefore, is identifying the analytical instrumentation that can deliver those necessary insights.

Analytical protocols for the biopharma industry continue to evolve in order to meet the need for increasing insight, not only for QbD but, more broadly, for industry progression. Identifying a certain issue as important (e.g., protein aggregation or the potential for sub visible particles to trigger an immunogenic response) creates a requirement for reliable detection. However, understanding the mechanisms that give rise to a problem and learning how to control those calls for additional layers of insight. As our understanding of the fundamentals of biologic behavior grows, so too does the requirement to dig deeper for data to support further progress. Traditional, well-established techniques, as well as innovative newcomers and hybrids that lie somewhere between the two, all have a role to play in helping regulators and developers reach a level of understanding and control that will ensure the continued innovation of safe and effective products.

### CONCLUSIONS:

QbD has been gaining an increasing acceptance from the pharmaceutical industry as well as from regulatory authorities. The number of QbD drug submissions has been steadily increasing for small molecules, and the first QbD submissions have already been reported for biologics as well. One of the key elements on which the authorities focus on during the review process of QbD submissions is how the connection between defining QTPP, identifying CQAs, and selecting CPPs is established. The use of risk-based methods is anticipated to create these connections; however, the approaches are influenced by the characteristics of the product and the amount of existing prior knowledge. Increased process understanding is an important cornerstone of the QbD paradigm. The novel approaches reported in this study for CPP risk assessment (clustering of process parameters in processing and physiology, inclusion of the factor “Complexity” in the risk assessment tool) are an important step towards this paradigm change. The integration of these findings into bio similar applications via tailored risk management approaches triggers the ultimate goal of pharmaceutical development, which is product quality. As essential novelty of this contribution, those tailored tools and the proposed workflow, can now be used generically for early bioprocess development of bio similar along QbD principles. The integration of similar risk-based approaches into QbD submissions is expected to be encouraged by the authorities, as indicated by the ICH Q10 guideline and QbD pilot programs. The advantage for the industry is not supposed to be any reduction of regulatory requirements but rather opportunities for more flexible approaches to meet these requirements. Over the long term, this flexibility can lead to the promised benefits of QbD such as reduction of development costs and time. These conclusions confirm risk management as an important

element of the implementation of QbD principles for bio similar development in the future.

#### ACKNOWLEDGEMENT:

Authors wish to thanks Oman Pharmaceutical Products Co. LLC, for providing library facility to carry out this review study.

#### REFERENCES:

- Zalai D, Dietzsch C, Herwig C. Risk based process development of Biosimilars as part of the Quality by Design Paradigm. *J Pharm Sci Technol*, 2013; 67(6): 569-580.
- Buket A, Sezer AD, Yegen G, Kuscü L. QbD implementation in Biotechnological products-Development studies.
- Aksu B, Paradkar A, Matas M, Ozer O, Guneri T, York P. Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression. *AAPS PharmSciTech*, 2012; 13(4): 1138–1146.
- Aksu B, Paradkar A, Matas M, Ozer O, Guneri T, York P. A quality by Design Approach Using Artificial Intelligence Techniques to Control the Critical Quality Attributes of Ramipril Tablets Manufactured by Wet Granulation. *Pharm Dev Technol*, 2013; 18(1): 236–245.
- Rathore AS, *et al.* Quality by Design for Biotechnology Products Part 3. *Biopharm Int*, 2010; 23(1): 36–45.
- Aksu B. Quality by Design (QbD) Roadmap. *Control Released Society Indian Chapter*, 2015; 7: 25-28.
- Arora T, *et al.* Quality by Design for Biotechnology Products Part 1. *Biopharm Int*, 2009; 22(11): 26-36.
- Aksu B, Aydogan M, Kanik B, Aksoy E. A Flexible Regulatory Approach for Different Raw Materials Suppliers Using QbD Principles. *Res J Pharm Biol Chem Sci*, 2013; 4(4): 358-372.
- Robert JL. Pharmaceutical Development Q8(R2), ICH Harmonised Tripartite Guideline. Kuala Lumpur: International Conference on Harmonisation; 2010.
- Quality Risk Management Q9, ICH Harmonised Tripartite Guideline, 2005.
- Pharmaceutical Quality System Q10, ICH Harmonised Tripartite Guideline, 2008.
- Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), (Endorsed) 2014.
- Pharmaceutical Development Report Example QbD for MR Generic Drugs. Quality by Design for ANDAs: An Example for Modified Release Dosage Forms, 2011.
- McCurdy V. Quality by Design in Process Understanding: For Scale Up and Manufacture of Active Ingredients. 1st ed. Germany: Wiley VCH; 2011.
- ICH Quality Implementation Working Group Points to Consider (R2), ICH Endorsed Guide for ICH Q8/Q9/Q10 Implementation, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2011.
- Aksu B, Yegen G. New Quality Concepts in Pharmaceuticals. *MUSBED*, 2014; 4(2): 96-104.
- Rathore AS, *et al.* Quality by Design for Biotechnology Products-Part 2. *Biopharm Int*, 2009; 22(12): 42–58.
- Roy S. Quality by Design: A Holistic Concept of Building Quality in Pharmaceuticals. *Int J Pharm Biomed Res*, 2012; 3(2): 100–108.
- Varu RK, Khanna A. Opportunities and Challenges to Implementing Quality by Design Approach in Generic Drug Development. *J Gen Med*, 2010; 7: 60-73.
- Trivedi B, *et al.* Quality by Design (QbD) in Pharmaceuticals. *Int J Pharm Pharm Sci*, 2012; 4(1): 17-29.
- Rathore AS. Quality by Design for Biologics and Biosimilars. *Pharm Technol*, 2011; 35(3): 64-66.
- Walsh G, editor. *Pharmaceutical Biotechnology- Concepts and Applications*. England: John Wiley & Sons Ltd; 2007. pp. 121–171.
- Conner J, Wuchterl D, Lopez M, Minshall B, Prusti R, Bocclair D, *et al.* The Biomanufacturing of Biotechnology Products. In: Craig S, editor. *Biotechnology Entrepreneurship*. 1st ed. Oxford, UK: Elsevier Inc; 2014. pp. 351-385.
- Sommerfeld S, Strube J. Challenges in biotechnology production-Generic Processes and Process Optimization for Monoclonal Antibodies. *Chem Eng Process*, 2005; 44(10): 1123-1137.
- Arora I. Chromatographic Methods for the Purification of Monoclonal Antibodies and Their Alternatives: A Review. *Int J Emer Technol Adv Eng*, 2013; 3(10): 475-481.
- Gronemeyer P, Ditz R, Strube J. Trends in Upstream and Downstream Process Development for Antibody Manufacturing. *Bioeng J Rev*, 2014; 1: 188–212.
- Liu HF, Ma J, Winter C, Bayer R. Recovery and Purification Process Development for Monoclonal Antibody Production. *Mabs J*, 2010; 2(5): 480-499.
- Meitz A, Sagmeister P, Langemann T, Herwig C. An Integrated Downstream Process Development Strategy along QbD Principles. *Bioeng J*, 2014; 1(4): 213-230.
- Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell Culture Processes for

- Monoclonal Antibody Production. *Mabs J*, 2010; 2(5): 466-477.
30. Pohlscheidt M, Charaniya S, Bork C, Jenzsch M, Noetzel TL, Luebbert A. Bioprocess and Fermentation Monitoring. In: Michael CF, editor. *Upstream Industrial Biotechnology: Equipment, Process Design, Sensing, Control, and cGMP Operations*. Vol. 2, 1st ed. New York: John Wiley & Sons Inc; 2013. pp. 1471-1491.
  31. Weiner GJ. Building Better Monoclonal Antibody Based Therapeutics. *Nat Rev Cancer*, 2015; 15: 361-370.
  32. A Mab: A Case Study in Bioprocess Development. Product Development and Realization Case Study A Mab. Thiland; CMC Biotech Working Group; 2009.
  33. Feroz JF, Hershenson S, Khan MA, Martin MS, editors. *Quality by Design for Biopharmaceutical Drug Product Development*. New York, USA: Springer LLC; 2015.
  34. FDA Guidance for Industry: Q8(R2) Pharmaceutical Development. Revision 2, 2009.
  35. ICH Harmonised Tripartite Guideline Q6B. Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products, Current Step 4 Version, 1999.
  36. Rathore AS. Roadmap for Implementation of Quality by Design (QbD) for Biotechnology Products. *Trends Biotechnol*, 2009; 27(9): 546-553.
  37. Optimization for Monoclonal Antibodies. *Chemical Engineering and Processing: Process Intensification*, 2005; 44(10): 1123-1137.
  38. Kuchibhatla J, Hunt C, Holdread S, Brooks JW. A Rapid and Effective Screening Process of Animal Component Free Hydrolysates to Increase Cell Performance. Boston: IBC Bioprocess International Conference; 2004.
  39. Fletcher T. Designing Culture Media for Recombinant Protein Production a Rational Approach. *Bioprocess Int*, 2005; 3: 30-36.
  40. Sushila D, Chavan SD, Pimpodkar NV, Kadam AS, Gaikwad PS. Quality by Design. *Res Rev J Pharm Qual Assur*, 2015; 1(2): 18-24.

**Conflict of Interest:** None

**Source of Funding:** Nil

**Paper Citation:** Das P, *et al.* Formulation and evaluation of Herbal Powdered Shampoo. *J Pharm Adv Res*, 2018; 1(4): 198-216.